• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二级预防中的血脂控制:基层医疗的多中心观察性研究

[Lipid control in secondary prevention: multicenter observational study in primary care].

作者信息

Brotons C, Maiques A, Mostaza J, Pintó X, Vilaseca J

机构信息

EAP Sardenya, Servei Català de la Salut, Barcelona, Spain.

出版信息

Aten Primaria. 2004 Jun 30;34(2):81-6. doi: 10.1016/s0212-6567(04)79464-0.

DOI:10.1016/s0212-6567(04)79464-0
PMID:15225529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7668961/
Abstract

OBJECTIVE

To assess the implementation of pharmacological and non-pharmacological treatment in coronary patients followed in primary care.

DESIGN

Observational prospective study of 6 months of follow-up.

SETTING

Primary care centers all over Spain.

PARTICIPANTS

Men and women, between 18 and 75 years old, diagnosed in the last 3 years of myocardial infarction, stable angina, and unstable angina, with cholesterol levels higher than the lipid therapeutical goal recommended by the Guía de Prevención Cardiovascular del Programa de Actividades y de Promoción de la Salud de la Sociedad Española de Medicina de Familia y Comunitaria. Patients were recruited between february of 1998 and july of 1999, and were followed for 6 months.

OUTCOME MEASUREMENTS

Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, weight, height, body mass index, systolic and diastolic blood pressure (SBP and DBP).

RESULTS

4464 patients were included, mean age of 59 years (range, 20-96), 60% men. At 6 months, 66% of the patients had a cholesterol level higher than 200 mg/dL, 55% had LDL-C higher than 130 mg/dL, and 11% had triglycerides higher than 190 mg/dL. At 6 months a reduction of 70 mg/dL of total cholesterol, of 52 mg/dL of triglycerides, and of 51 mg/dL of LDL-C, and an increase of 4 mg/dL of HDL-Cholesterol was observed. Also, SBP and DBP were reduced 5 mm Hg and 3 mm Hg.

CONCLUSIONS

Although a clear improved was observed in the control of lipids and other risk factors, there is still a considerable potential to raise standards in secondary prevention of coronary patients followed in primary care concerning control of cardiovascular risk factors, particularly total cholesterol and lipid fractions.

摘要

目的

评估在初级保健中接受随访的冠心病患者的药物治疗和非药物治疗的实施情况。

设计

为期6个月的前瞻性观察研究。

地点

西班牙各地的初级保健中心。

参与者

年龄在18至75岁之间的男性和女性,在过去3年中被诊断为心肌梗死、稳定型心绞痛和不稳定型心绞痛,胆固醇水平高于西班牙家庭和社区医学学会健康促进与活动计划心血管预防指南推荐的脂质治疗目标。患者于1998年2月至1999年7月招募,并随访6个月。

观察指标

总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、体重、身高、体重指数、收缩压和舒张压(SBP和DBP)。

结果

纳入4464例患者,平均年龄59岁(范围20 - 96岁),60%为男性。6个月时,66%的患者胆固醇水平高于200mg/dL,55%的患者低密度脂蛋白胆固醇高于130mg/dL,11%的患者甘油三酯高于190mg/dL。6个月时观察到总胆固醇降低70mg/dL,甘油三酯降低52mg/dL,低密度脂蛋白胆固醇降低51mg/dL,高密度脂蛋白胆固醇升高4mg/dL。此外,收缩压和舒张压分别降低了5mmHg和3mmHg。

结论

尽管在血脂和其他危险因素的控制方面有明显改善,但在初级保健中接受随访的冠心病患者的二级预防中,在控制心血管危险因素,特别是总胆固醇和血脂成分方面,仍有相当大的提升标准的潜力。

相似文献

1
[Lipid control in secondary prevention: multicenter observational study in primary care].二级预防中的血脂控制:基层医疗的多中心观察性研究
Aten Primaria. 2004 Jun 30;34(2):81-6. doi: 10.1016/s0212-6567(04)79464-0.
2
A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting(estudio del control de las hiperlipidemiasen atención primaria): the cheap study.阿托伐他汀在初级保健环境中疗效和耐受性的一项为期六个月的多中心、开放标签、非对比性、前瞻性观察性研究(初级保健中高脂血症控制研究):廉价研究
Curr Ther Res Clin Exp. 2003 Jun;64(6):338-54. doi: 10.1016/S0011-393X(03)00090-0.
3
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.洛伐他汀对胆固醇水平正常的男性和女性急性冠脉事件的一级预防:空军/德州冠状动脉粥样硬化预防研究(AFCAPS/TexCAPS)的结果
JAMA. 1998 May 27;279(20):1615-22. doi: 10.1001/jama.279.20.1615.
4
Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.基层医疗中总胆固醇水平大于5.17 mmol/L(200 mg/dL)患者的低高密度脂蛋白胆固醇及其他冠心病危险因素。CEN的一份报告
J Am Board Fam Pract. 1991 Sep-Oct;4(5):285-97.
5
[La educación multimedia como apoyo en el manejo de pacientes con diabetes tipo 2. Estudio cuasi experimental].[多媒体教育对2型糖尿病患者管理的辅助作用。准实验研究]
Cir Cir. 2018;86(5):404-411. doi: 10.24875/CIRU.18000119.
6
Lowering LDL cholesterol in adults: a prospective, community-based practice initiative.降低成人低密度脂蛋白胆固醇:一项基于社区的前瞻性实践倡议。
Am J Med. 2008 Jul;121(7):604-10. doi: 10.1016/j.amjmed.2008.02.031. Epub 2008 Jun 4.
7
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.降脂药物联合治疗对冠心病且胆固醇水平“正常”患者的影响。一项随机、安慰剂对照试验。哈佛动脉粥样硬化逆转项目(HARP)研究组。
Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001.
8
[Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].[2000年西班牙的胆固醇血症控制。心血管疾病预防工具。卫生与消费部、西班牙心脏病学会和西班牙动脉硬化学会]
Rev Esp Salud Publica. 2000 May-Jun;74(3):215-53.
9
Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.回顾性病历审查结果,以确定接受高剂量调脂药物处方者治疗的患者在实现血脂目标方面的改善情况。
J Manag Care Pharm. 2006 Nov-Dec;12(9):745-51. doi: 10.18553/jmcp.2006.12.9.745.
10
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.阿托伐他汀治疗达到国家胆固醇教育计划目标与“常规”治疗用于二级冠心病预防的比较。希腊阿托伐他汀与冠心病评估(GREACE)研究。
Curr Med Res Opin. 2002;18(4):220-8. doi: 10.1185/030079902125000787.

本文引用的文献

1
[Secondary prevention of myocardial infarction and health-related quality of life].心肌梗死的二级预防与健康相关生活质量
Med Clin (Barc). 2002 Jun 8;119(1):9-12.
2
Secondary prevention in 24, 431 patients with coronary heart disease: survey in primary care.24431例冠心病患者的二级预防:初级保健调查
BMJ. 2001 Jun 16;322(7300):1463. doi: 10.1136/bmj.322.7300.1463.
3
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.来自15个国家的冠心病患者的生活方式、危险因素管理及药物治疗的应用;欧洲心脏调查项目EUROASPIRE II的主要结果
Eur Heart J. 2001 Apr;22(7):554-72. doi: 10.1053/euhj.2001.2610.
4
[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)].初级保健中缺血性心脏病的二级预防(PRESENCIAP)
Aten Primaria. 2001 Jan;27(1):29-32. doi: 10.1016/S0212-6567(01)78769-0.
5
[Secondary prevention of ischemic heart disease in the Cuidad Real Province, Spain. Effectiveness of lipid-lowering therapy in primary health care].[西班牙雷阿尔城省缺血性心脏病的二级预防。初级卫生保健中降脂治疗的有效性]
Med Clin (Barc). 2000 Sep 23;115(9):321-5.
6
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.他汀类药物对冠心病风险的影响:随机对照试验的荟萃分析
JAMA. 1999;282(24):2340-6. doi: 10.1001/jama.282.24.2340.
7
Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group.心肌梗死和心绞痛患者全科医疗后续护理的随机对照试验:南安普顿心脏综合护理项目(SHIP)的最终结果。SHIP协作组
BMJ. 1999 Mar 13;318(7185):706-11. doi: 10.1136/bmj.318.7185.706.
8
Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care.冠心病的二级预防:初级保健中护士主导诊所的随机试验
Heart. 1998 Nov;80(5):447-52. doi: 10.1136/hrt.80.5.447.
9
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.临床实践中冠心病的预防:欧洲及其他学会冠心病预防联合特别工作组第二次报告建议
Atherosclerosis. 1998 Oct;140(2):199-270. doi: 10.1016/s0021-9150(98)90209-x.
10
Is prophylactic treatment after myocardial infarction evidence-based?心肌梗死后的预防性治疗有循证依据吗?
Fam Pract. 1998 Oct;15(5):457-61. doi: 10.1093/fampra/15.5.457.